Provider: NIHR Journals Library
Content:text/plain; charset="UTF-8"
TY  - JOUR
LB  - 1.
AU  - Raghu, G
AU  - Remy-Jardin, M
AU  - Myers, JL
AU  - Richeldi, L
AU  - Ryerson, CJ
AU  - Lederer, DJ
TI  - Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline
J2  - Am J Respir Crit Care Med
PY  - 2018
VL  - 198
SP  - e44
EP  - e68
UR  - https://doi.org/10.1164/rccm.201807-1255ST
ER  - 
TY  - JOUR
LB  - 2.
AU  - Nicholson, AG
AU  - Colby, TV
AU  - du Bois, RM
AU  - Hansell, DM
AU  - Wells, AU
TI  - The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis
J2  - Am J Respir Crit Care Med
PY  - 2000
VL  - 162
SP  - 2213
EP  - 2217
UR  - https://doi.org/10.1164/ajrccm.162.6.2003049
ER  - 
TY  - JOUR
LB  - 3.
AU  - Navaratnam, V
AU  - Fleming, KM
AU  - West, J
AU  - Smith, CJP
AU  - Jenkins, RG
AU  - Fogarty, A
AU  - Hubbard, RB
TI  - The rising incidence of idiopathic pulmonary fibrosis in the UK
J2  - Thorax
PY  - 2011
VL  - 66
SP  - 462
EP  - 467
UR  - https://doi.org/10.1136/thx.2010.148031
ER  - 
TY  - JOUR
LB  - 4.
AU  - Macpherson, KJ
AU  - Lewsey, JD
AU  - Jhund, PS
AU  - Gillies, M
AU  - Chalmers, JW
AU  - Redpath, A
TI  - Trends in incidence and in short term survival following a subarachnoid haemorrhage in Scotland, 1986–2005: a retrospective cohort study
J2  - BMC Neurol
PY  - 2011
VL  - 11
SP  - 38
UR  - https://doi.org/10.1186/1471-2377-11-38
ER  - 
TY  - JOUR
LB  - 5.
AU  - Navaratnam, V
AU  - Fogarty, AW
AU  - Glendening, R
AU  - McKeever, T
AU  - Hubbard, RB
TI  - The increasing secondary care burden of idiopathic pulmonary fibrosis: hospital admission trends in England from 1998 to 2010
J2  - Chest
PY  - 2013
VL  - 143
SP  - 1078
EP  - 1084
UR  - https://doi.org/10.1378/chest.12-0803
ER  - 
TY  - JOUR
LB  - 6.
AU  - Collard, HR
AU  - Ward, AJ
AU  - Lanes, S
AU  - Cortney Hayflinger, D
AU  - Rosenberg, DM
AU  - Hunsche, E
TI  - Burden of illness in idiopathic pulmonary fibrosis
J2  - J Med Econ
PY  - 2012
VL  - 15
SP  - 829
EP  - 835
UR  - https://doi.org/10.3111/13696998.2012.680553
ER  - 
TY  - JOUR
LB  - 7.
AU  - Lee, AS
AU  - Mira-Avendano, I
AU  - Ryu, JH
AU  - Daniels, CE
TI  - The burden of idiopathic pulmonary fibrosis: an unmet public health need
J2  - Respir Med
PY  - 2014
VL  - 108
SP  - 955
EP  - 967
UR  - https://doi.org/10.1016/j.rmed.2014.03.015
ER  - 
TY  - JOUR
LB  - 8.
AU  - Raghu, G
AU  - Collard, HR
AU  - Egan, JJ
AU  - Martinez, FJ
AU  - Behr, J
AU  - Brown, KK
TI  - An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management
J2  - Am J Respir Crit Care Med
PY  - 2011
VL  - 183
SP  - 788
EP  - 824
UR  - https://doi.org/10.1164/rccm.2009-040GL
ER  - 
TY  - JOUR
LB  - 9.
AU  - Raghu, G
AU  - Anstrom, KJ
AU  - King, TE
AU  - Lasky, JA
AU  - Martinez, FJ
AU  - Idiopathic Pulmonary Fibrosis Clinical Research Network
TI  - Prednisone, azathioprine, andN-acetylcysteine for pulmonary fibrosis
J2  - N Engl J Med
PY  - 2012
VL  - 366
SP  - 1968
EP  - 1977
UR  - https://doi.org/10.1056/NEJMoa1113354
ER  - 
TY  - JOUR
LB  - 10.
AU  - Kubo, H
AU  - Nakayama, K
AU  - Yanai, M
AU  - Suzuki, T
AU  - Yamaya, M
AU  - Watanabe, M
AU  - Sasaki, H
TI  - Anticoagulant therapy for idiopathic pulmonary fibrosis
J2  - Chest
PY  - 2005
VL  - 128
SP  - 1475
EP  - 1482
UR  - https://doi.org/10.1378/chest.128.3.1475
ER  - 
TY  - JOUR
LB  - 11.
AU  - Noth, I
AU  - Anstrom, KJ
AU  - Calvert, SB
AU  - de Andrade, J
AU  - Flaherty, KR
AU  - Glazer, C
TI  - A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis
J2  - Am J Respir Crit Care Med
PY  - 2012
VL  - 186
SP  - 88
EP  - 95
UR  - https://doi.org/10.1164/rccm.201202-0314OC
ER  - 
TY  - JOUR
LB  - 12.
AU  - Demedts, M
AU  - Behr, J
AU  - Buhl, R
AU  - Costabel, U
AU  - Dekhuijzen, R
AU  - Jansen, HM
TI  - High-dose acetylcysteine in idiopathic pulmonary fibrosis
J2  - N Engl J Med
PY  - 2005
VL  - 353
SP  - 2229
EP  - 2242
UR  - https://doi.org/10.1056/NEJMoa042976
ER  - 
TY  - JOUR
LB  - 13.
AU  - Martinez, FJ
AU  - de Andrade, JA
AU  - Anstrom, KJ
AU  - King, TE
AU  - Raghu, G
AU  - Idiopathic Pulmonary Fibrosis Clinical Research Network
TI  - Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis
J2  - N Engl J Med
PY  - 2014
VL  - 370
SP  - 2093
EP  - 2101
UR  - https://doi.org/10.1056/NEJMoa1401739
ER  - 
TY  - JOUR
LB  - 14.
AU  - Noble, PW
AU  - Albera, C
AU  - Bradford, WZ
AU  - Costabel, U
AU  - Glassberg, MK
AU  - Kardatzke, D
TI  - Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
J2  - Lancet
PY  - 2011
VL  - 377
SP  - 1760
EP  - 1769
UR  - https://doi.org/10.1016/S0140-6736(11)60405-4
ER  - 
TY  - JOUR
LB  - 15.
AU  - Richeldi, L
AU  - Costabel, U
AU  - Selman, M
AU  - Kim, DS
AU  - Hansell, DM
AU  - Nicholson, AG
TI  - Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis
J2  - N Engl J Med
PY  - 2011
VL  - 365
SP  - 1079
EP  - 1087
UR  - https://doi.org/10.1056/NEJMoa1103690
ER  - 
TY  - JOUR
LB  - 16.
AU  - Raghu, G
AU  - Rochwerg, B
AU  - Zhang, Y
AU  - Garcia, CA
AU  - Azuma, A
AU  - Behr, J
TI  - An Official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline
J2  - Am J Respir Crit Care Med
PY  - 2015
VL  - 192
SP  - e3
EP  - 19
UR  - https://doi.org/10.1164/rccm.201506-1063ST
ER  - 
TY  - JOUR
LB  - 17.
AU  - Nathan, SD
AU  - Albera, C
AU  - Bradford, WZ
AU  - Costabel, U
AU  - Glaspole, I
AU  - Glassberg, MK
TI  - Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis
J2  - Lancet Respir Med
PY  - 2017
VL  - 5
SP  - 33
EP  - 41
UR  - https://doi.org/10.1016/S2213-2600(16)30326-5
ER  - 
TY  - ELEC
LB  - 18.
AU  - National Institute for Health and Care Excellence
TI  - Idiopathic Pulmonary Fibrosis in Adults: Diagnosis and Management
PY  - 2013
UR  - www.nice.org.uk/guidance/cg163
M1  - 31 March 2020
ER  - 
TY  - JOUR
LB  - 19.
AU  - Skandamis, A
AU  - Kani, C
AU  - Markantonis, SL
AU  - Souliotis, K
TI  - Systematic review and network meta-analysis of approved medicines for the treatment of idiopathic pulmonary fibrosis
J2  - J Drug Assess
PY  - 2019
VL  - 8
SP  - 55
EP  - 61
UR  - https://doi.org/10.1080/21556660.2019.1597726
ER  - 
TY  - JOUR
LB  - 20.
AU  - Varney, VA
AU  - Parnell, HM
AU  - Salisbury, DT
AU  - Ratnatheepan, S
AU  - Tayar, RB
TI  - A double blind randomised placebo controlled pilot study of oral co-trimoxazole in advanced fibrotic lung disease
J2  - Pulm Pharmacol Ther
PY  - 2008
VL  - 21
SP  - 178
EP  - 187
UR  - https://doi.org/10.1016/j.pupt.2007.02.001
ER  - 
TY  - JOUR
LB  - 21.
AU  - Shulgina, L
AU  - Cahn, AP
AU  - Chilvers, ER
AU  - Parfrey, H
AU  - Clark, AB
AU  - Wilson, EC
TI  - Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial
J2  - Thorax
PY  - 2013
VL  - 68
SP  - 155
EP  - 162
UR  - https://doi.org/10.1136/thoraxjnl-2012-202403
ER  - 
TY  - JOUR
LB  - 22.
AU  - Wilson, EC
AU  - Shulgina, L
AU  - Cahn, AP
AU  - Chilvers, ER
AU  - Parfrey, H
AU  - Clark, AB
TI  - Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: an economic evaluation alongside a randomised controlled trial
J2  - Pharmacoeconomics
PY  - 2014
VL  - 32
SP  - 87
EP  - 99
UR  - https://doi.org/10.1007/s40273-013-0112-z
ER  - 
TY  - JOUR
LB  - 23.
AU  - Oda, K
AU  - Yatera, K
AU  - Fujino, Y
AU  - Ishimoto, H
AU  - Nakao, H
AU  - Hanaka, T
TI  - Efficacy of concurrent treatments in idiopathic pulmonary fibrosis patients with a rapid progression of respiratory failure: an analysis of a national administrative database in Japan
J2  - BMC Pulm Med
PY  - 2016
VL  - 16
SP  - 91
UR  - https://doi.org/10.1186/s12890-016-0253-x
ER  - 
TY  - JOUR
LB  - 24.
AU  - Shulgina, L
AU  - Cahn, AP
AU  - Chilvers, ER
AU  - Parfrey, H
AU  - Clark, AB
AU  - Wilson, EC
TI  - Author’s response: co-trimoxazole treatment in idiopathic pulmonary fibrosis
J2  - Thorax
PY  - 2013
VL  - 68
SP  - 884
EP  - 885
UR  - https://doi.org/10.1136/thoraxjnl-2013-203765
ER  - 
TY  - JOUR
LB  - 25.
AU  - Atkins, CP
AU  - Loke, Y
AU  - Wilson, AM
TI  - S16 Outcomes in idiopathic pulmonary fibrosis: a meta-analysis from placebo controlled trials
J2  - Thorax
PY  - 2013
VL  - 68
SP  - A11
UR  - https://doi.org/10.1136/thoraxjnl-2013-204457.23
ER  - 
TY  - JOUR
LB  - 26.
AU  - Müllerova, H
AU  - Chigbo, C
AU  - Hagan, GW
AU  - Woodhead, MA
AU  - Miravitlles, M
AU  - Davis, KJ
AU  - Wedzicha, JA
TI  - The natural history of community-acquired pneumonia in COPD patients: a population database analysis
J2  - Respir Med
PY  - 2012
VL  - 106
SP  - 1124
EP  - 1133
UR  - https://doi.org/10.1016/j.rmed.2012.04.008
ER  - 
TY  - JOUR
LB  - 27.
AU  - Olson, AL
AU  - Swigris, JJ
AU  - Raghu, G
AU  - Brown, KK
TI  - Seasonal variation: mortality from pulmonary fibrosis is greatest in the winter
J2  - Chest
PY  - 2009
VL  - 136
SP  - 16
EP  - 22
UR  - https://doi.org/10.1378/chest.08-0703
ER  - 
TY  - JOUR
LB  - 28.
AU  - Richter, AG
AU  - Stockley, RA
AU  - Harper, L
AU  - Thickett, DR
TI  - Pulmonary infection in Wegener granulomatosis and idiopathic pulmonary fibrosis
J2  - Thorax
PY  - 2009
VL  - 64
SP  - 692
EP  - 697
UR  - https://doi.org/10.1136/thx.2008.110445
ER  - 
TY  - JOUR
LB  - 29.
AU  - Vidal, S
AU  - de la Horra, C
AU  - Martín, J
AU  - Montes-Cano, MA
AU  - Rodríguez, E
AU  - Respaldiza, N
TI  - Pneumocystis jiroveciicolonisation in patients with interstitial lung disease
J2  - Clin Microbiol Infect
PY  - 2006
VL  - 12
SP  - 231
EP  - 235
UR  - https://doi.org/10.1111/j.1469-0691.2005.01337.x
ER  - 
TY  - JOUR
LB  - 30.
AU  - Garzoni, C
AU  - Brugger, SD
AU  - Qi, W
AU  - Wasmer, S
AU  - Cusini, A
AU  - Dumont, P
TI  - Microbial communities in the respiratory tract of patients with interstitial lung disease
J2  - Thorax
PY  - 2013
VL  - 68
SP  - 1150
EP  - 1156
UR  - https://doi.org/10.1136/thoraxjnl-2012-202917
ER  - 
TY  - JOUR
LB  - 31.
AU  - Molyneaux, PL
AU  - Cox, MJ
AU  - Mallia, P
AU  - Johnston, SL
AU  - Moffatt, MF
AU  - Cookson, WOC
AU  - Maher, TM
TI  - S38 The role of the respiratory microbiome in idiopathic pulmonary fibrosis
J2  - Thorax
PY  - 2013
VL  - 68
SP  - A22
UR  - https://doi.org/10.1136/thoraxjnl-2013-204457.45
ER  - 
TY  - JOUR
LB  - 32.
AU  - Hilty, M
AU  - Burke, C
AU  - Pedro, H
AU  - Cardenas, P
AU  - Bush, A
AU  - Bossley, C
TI  - Disordered microbial communities in asthmatic airways
J2  - PLOS ONE
PY  - 2010
VL  - 5
SP  - e8578
UR  - https://doi.org/10.1371/journal.pone.0008578
ER  - 
TY  - JOUR
LB  - 33.
AU  - Han, MKE-D
AU  - Zhou, Y
AU  - Tayob, N
AU  - Murray, S
AU  - Flaherty, KR
AU  - Huffnagle, GB
AU  - Martinez, FJ
TI  - The IPF microbiome: analysis from the COMET study
J2  - Am J Respir Crit Care Med
PY  - 2013
VL  - 187
SP  - A3769
ER  - 
TY  - JOUR
LB  - 34.
AU  - Savici, D
AU  - Campbell, PA
AU  - King, TE
TI  - Bronchoalveolar macrophages from patients with idiopathic pulmonary fibrosis are unable to kill facultative intracellular bacteria
J2  - Am Rev Respir Dis
PY  - 1989
VL  - 139
SP  - 22
EP  - 27
UR  - https://doi.org/10.1164/ajrccm/139.1.22
ER  - 
TY  - JOUR
LB  - 35.
AU  - Samara, KD
AU  - Antoniou, KM
AU  - Karagiannis, K
AU  - Margaritopoulos, G
AU  - Lasithiotaki, I
AU  - Koutala, E
AU  - Siafakas, NM
TI  - Expression profiles of Toll-like receptors in non-small cell lung cancer and idiopathic pulmonary fibrosis
J2  - Int J Oncol
PY  - 2012
VL  - 40
SP  - 1397
EP  - 1404
UR  - https://doi.org/10.3892/ijo.2012.1374
ER  - 
TY  - JOUR
LB  - 36.
AU  - Hogaboam, CM
AU  - Trujillo, G
AU  - Martinez, FJ
TI  - Aberrant innate immune sensing leads to the rapid progression of idiopathic pulmonary fibrosis
J2  - Fibrogenesis Tissue Repair
PY  - 2012
VL  - 5
IS  - Suppl. 1
SP  - S3
UR  - https://doi.org/10.1186/1755-1536-5-S1-S3
ER  - 
TY  - JOUR
LB  - 37.
AU  - Stegeman, CA
AU  - Tervaert, JW
AU  - de Jong, PE
AU  - Kallenberg, CG
TI  - Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener’s granulomatosis. Dutch Co-Trimoxazole Wegener Study Group
J2  - N Engl J Med
PY  - 1996
VL  - 335
SP  - 16
EP  - 20
UR  - https://doi.org/10.1056/NEJM199607043350103
ER  - 
TY  - JOUR
LB  - 38.
AU  - Zycinska, K
AU  - Wardyn, KA
AU  - Zielonka, TM
AU  - Krupa, R
AU  - Lukas, W
TI  - Co-trimoxazole and prevention of relapses of PR3-ANCA positive vasculitis with pulmonary involvement
J2  - Eur J Med Res
PY  - 2009
VL  - 14
IS  - Suppl. 4
SP  - 265
EP  - 267
UR  - https://doi.org/10.1186/2047-783X-14-S4-265
ER  - 
TY  - JOUR
LB  - 39.
AU  - Harvath, L
AU  - Yancey, KB
AU  - Katz, SI
TI  - Selective inhibition of human neutrophil chemotaxis toN-formyl-methionyl-leucyl-phenylalanine by sulfones
J2  - J Immunol
PY  - 1986
VL  - 137
SP  - 1305
EP  - 1311
ER  - 
TY  - JOUR
LB  - 40.
AU  - Suda, T
AU  - Suzuki, Y
AU  - Matsui, T
AU  - Inoue, T
AU  - Niide, O
AU  - Yoshimaru, T
TI  - Dapsone suppresses human neutrophil superoxide production and elastase release in a calcium-dependent manner
J2  - Br J Dermatol
PY  - 2005
VL  - 152
SP  - 887
EP  - 895
UR  - https://doi.org/10.1111/j.1365-2133.2005.06559.x
ER  - 
TY  - JOUR
LB  - 41.
AU  - Anderson, R
AU  - Grabow, G
AU  - Oosthuizen, R
AU  - Theron, A
AU  - Van Rensburg, AJ
TI  - Effects of sulfamethoxazole and trimethoprim on human neutrophil and lymphocyte functions in vitro: in vivo effects of co-trimoxazole
J2  - Antimicrob Agents Chemother
PY  - 1980
VL  - 17
SP  - 322
EP  - 326
UR  - https://doi.org/10.1128/AAC.17.3.322
ER  - 
TY  - JOUR
LB  - 42.
AU  - Siegel, JP
AU  - Remington, JS
TI  - Effect of antimicrobial agents on chemiluminescence of human polymorphonuclear leukocytes in response to phagocytosis
J2  - J Antimicrob Chemother
PY  - 1982
VL  - 10
SP  - 505
EP  - 515
UR  - https://doi.org/10.1093/jac/10.6.505
ER  - 
TY  - JOUR
LB  - 43.
AU  - Welch, WD
AU  - Davis, D
AU  - Thrupp, LD
TI  - Effect of antimicrobial agents on human polymorphonuclear leukocyte microbicidal function
J2  - Antimicrob Agents Chemother
PY  - 1981
VL  - 20
SP  - 15
EP  - 20
UR  - https://doi.org/10.1128/AAC.20.1.15
ER  - 
TY  - JOUR
LB  - 44.
AU  - Cantin, AM
AU  - North, SL
AU  - Fells, GA
AU  - Hubbard, RC
AU  - Crystal, RG
TI  - Oxidant-mediated epithelial cell injury in idiopathic pulmonary fibrosis
J2  - J Clin Invest
PY  - 1987
VL  - 79
SP  - 1665
EP  - 1673
UR  - https://doi.org/10.1172/JCI113005
ER  - 
TY  - JOUR
LB  - 45.
AU  - Felton, VM
AU  - Borok, Z
AU  - Willis, BC
TI  - N-acetylcysteine inhibits alveolar epithelial-mesenchymal transition
J2  - Am J Physiol Lung Cell Mol Physiol
PY  - 2009
VL  - 297
SP  - L805
EP  - L812
UR  - https://doi.org/10.1152/ajplung.00009.2009
ER  - 
TY  - JOUR
LB  - 46.
AU  - Psathakis, K
AU  - Mermigkis, D
AU  - Papatheodorou, G
AU  - Loukides, S
AU  - Panagou, P
AU  - Polychronopoulos, V
TI  - Exhaled markers of oxidative stress in idiopathic pulmonary fibrosis
J2  - Eur J Clin Invest
PY  - 2006
VL  - 36
SP  - 362
EP  - 367
UR  - https://doi.org/10.1111/j.1365-2362.2006.01636.x
ER  - 
TY  - JOUR
LB  - 47.
AU  - Behr, J
AU  - Maier, K
AU  - Krombach, F
AU  - Adelmann-Grill, BC
TI  - Pathogenetic significance of reactive oxygen species in diffuse fibrosing alveolitis
J2  - Am Rev Respir Dis
PY  - 1991
VL  - 144
SP  - 146
EP  - 150
UR  - https://doi.org/10.1164/ajrccm/144.1.146
ER  - 
TY  - JOUR
LB  - 48.
AU  - Crystal, RG
AU  - Bitterman, PB
AU  - Rennard, SI
AU  - Hance, AJ
AU  - Keogh, BA
TI  - Interstitial lung diseases of unknown cause. Disorders characterized by chronic inflammation of the lower respiratory tract (first of two parts)
J2  - N Engl J Med
PY  - 1984
VL  - 310
SP  - 154
EP  - 166
UR  - https://doi.org/10.1056/NEJM198401193100304
ER  - 
TY  - JOUR
LB  - 49.
AU  - Beeh, KM
AU  - Beier, J
AU  - Kornmann, O
AU  - Buhl, R
TI  - Neutrophilic inflammation in induced sputum of patients with idiopathic pulmonary fibrosis
J2  - Sarcoidosis Vasc Diffuse Lung Dis
PY  - 2003
VL  - 20
SP  - 138
EP  - 143
ER  - 
TY  - JOUR
LB  - 50.
AU  - Kinder, BW
AU  - Brown, KK
AU  - Schwarz, MI
AU  - Ix, JH
AU  - Kervitsky, A
AU  - King, TE
TI  - Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis
J2  - Chest
PY  - 2008
VL  - 133
SP  - 226
EP  - 232
UR  - https://doi.org/10.1378/chest.07-1948
ER  - 
TY  - JOUR
LB  - 51.
AU  - Chan, WY
AU  - Clark, AB
AU  - Wilson, AM
AU  - Loke, YK
AU  - TIPAC investigators
TI  - The effect of co-trimoxazole on serum potassium concentration: safety evaluation of a randomized controlled trial
J2  - Br J Clin Pharmacol
PY  - 2017
VL  - 83
SP  - 1808
EP  - 1814
UR  - https://doi.org/10.1111/bcp.13263
ER  - 
TY  - JOUR
LB  - 52.
AU  - Raghu, G
AU  - Collard, HR
AU  - Anstrom, KJ
AU  - Flaherty, KR
AU  - Fleming, TR
AU  - King, TE
TI  - Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials
J2  - Am J Respir Crit Care Med
PY  - 2012
VL  - 185
SP  - 1044
EP  - 1048
UR  - https://doi.org/10.1164/rccm.201201-0006PP
ER  - 
TY  - JOUR
LB  - 53.
AU  - Wells, AU
AU  - Behr, J
AU  - Costabel, U
AU  - Cottin, V
AU  - Poletti, V
AU  - Richeldi, L
AU  - European, IPF
TI  - Consensus Group. Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good
J2  - Thorax
PY  - 2012
VL  - 67
SP  - 938
EP  - 940
UR  - https://doi.org/10.1136/thoraxjnl-2012-202580
ER  - 
TY  - JOUR
LB  - 54.
AU  - Atkins, CP
AU  - Loke, YK
AU  - Wilson, AM
TI  - Outcomes in idiopathic pulmonary fibrosis: a meta-analysis from placebo controlled trials
J2  - Respir Med
PY  - 2014
VL  - 108
SP  - 376
EP  - 387
UR  - https://doi.org/10.1016/j.rmed.2013.11.007
ER  - 
TY  - JOUR
LB  - 55.
AU  - Zisman, DA
AU  - Schwarz, M
AU  - Anstrom, KJ
AU  - Collard, HR
AU  - Flaherty, KR
AU  - Hunninghake, GW
AU  - Idiopathic Pulmonary Fibrosis Clinical Research Network
TI  - A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis
J2  - N Engl J Med
PY  - 2010
VL  - 363
SP  - 620
EP  - 628
UR  - https://doi.org/10.1056/NEJMoa1002110
ER  - 
TY  - JOUR
LB  - 56.
AU  - du Bois, RM
AU  - Weycker, D
AU  - Albera, C
AU  - Bradford, WZ
AU  - Costabel, U
AU  - Kartashov, A
TI  - Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis
J2  - Am J Respir Crit Care Med
PY  - 2011
VL  - 184
SP  - 459
EP  - 466
UR  - https://doi.org/10.1164/rccm.201011-1790OC
ER  - 
TY  - JOUR
LB  - 57.
AU  - Hammond, M
AU  - Clark, AB
AU  - Cahn, AP
AU  - Chilvers, ER
AU  - Fraser, WD
AU  - Livermore, DM
TI  - The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary fibrosis with the Addition of Co-trimoxazole (EME-TIPAC): study protocol for a randomised controlled trial
J2  - Trials
PY  - 2018
VL  - 19
SP  - 89
UR  - https://doi.org/10.1186/s13063-018-2453-6
ER  - 
TY  - JOUR
LB  - 58.
AU  - Chan, TY
TI  - Co-trimoxazole-induced severe haemolysis: the experience of a large general hospital in Hong Kong
J2  - Pharmacoepidemiol Drug Saf
PY  - 1997
VL  - 6
SP  - 89
EP  - 92
UR  - https://doi.org/10.1002/(SICI)1099-1557(199703)6:2<89::AID-PDS261>3.0.CO;2-8
ER  - 
TY  - JOUR
LB  - 59.
AU  - Patel, AS
AU  - Siegert, RJ
AU  - Brignall, K
AU  - Gordon, P
AU  - Steer, S
AU  - Desai, SR
TI  - The development and validation of the King’s Brief Interstitial Lung Disease (K-BILD) health status questionnaire
J2  - Thorax
PY  - 2012
VL  - 67
SP  - 804
EP  - 810
UR  - https://doi.org/10.1136/thoraxjnl-2012-201581
ER  - 
TY  - JOUR
LB  - 60.
AU  - Nolan, CM
AU  - Birring, SS
AU  - Maddocks, M
AU  - Maher, TM
AU  - Patel, S
AU  - Barker, RE
TI  - King’s Brief Interstitial Lung Disease questionnaire: responsiveness and minimum clinically important difference
J2  - Eur Respir J
PY  - 2019
VL  - 54
SP  - 1900281
UR  - https://doi.org/10.1183/13993003.00281-2019
ER  - 
TY  - JOUR
LB  - 61.
AU  - Sinha, A
AU  - Patel, AS
AU  - Siegert, RJ
AU  - Bajwah, S
AU  - Maher, TM
AU  - Renzoni, EA
TI  - The King’s Brief Interstitial Lung Disease (KBILD) questionnaire: an updated minimal clinically important difference
J2  - BMJ Open Respir Res
PY  - 2019
VL  - 6
SP  - e000363
UR  - https://doi.org/10.1136/bmjresp-2018-000363
ER  - 
TY  - JOUR
LB  - 62.
AU  - Manali, ED
AU  - Lyberopoulos, P
AU  - Triantafillidou, C
AU  - Kolilekas, LF
AU  - Sotiropoulou, C
AU  - Milic-Emili, J
TI  - MRC Chronic Dyspnea Scale: relationships with cardiopulmonary exercise testing and 6-minute walk test in idiopathic pulmonary fibrosis patients: a prospective study
J2  - BMC Pulm Med
PY  - 2010
VL  - 10
SP  - 32
UR  - https://doi.org/10.1186/1471-2466-10-32
ER  - 
TY  - JOUR
LB  - 63.
AU  - Herdman, M
AU  - Gudex, C
AU  - Lloyd, A
AU  - Janssen, M
AU  - Kind, P
AU  - Parkin, D
TI  - Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
J2  - Qual Life Res
PY  - 2011
VL  - 20
SP  - 1727
EP  - 1736
UR  - https://doi.org/10.1007/s11136-011-9903-x
ER  - 
TY  - JOUR
LB  - 64.
AU  - Birring, SS
AU  - Prudon, B
AU  - Carr, AJ
AU  - Singh, SJ
AU  - Morgan, MD
AU  - Pavord, ID
TI  - Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ)
J2  - Thorax
PY  - 2003
VL  - 58
SP  - 339
EP  - 343
UR  - https://doi.org/10.1136/thorax.58.4.339
ER  - 
TY  - JOUR
LB  - 65.
AU  - Key, AL
AU  - Holt, K
AU  - Hamilton, A
AU  - Smith, JA
AU  - Earis, JE
TI  - Objective cough frequency in idiopathic pulmonary fibrosis
J2  - Cough
PY  - 2010
VL  - 6
SP  - 4
UR  - https://doi.org/10.1186/1745-9974-6-4
ER  - 
TY  - JOUR
LB  - 66.
AU  - Miller, MR
AU  - Hankinson, J
AU  - Brusasco, V
AU  - Burgos, F
AU  - Casaburi, R
AU  - Coates, A
TI  - Standardisation of spirometry
J2  - Eur Respir J
PY  - 2005
VL  - 26
SP  - 319
EP  - 338
UR  - https://doi.org/10.1183/09031936.05.00034805
ER  - 
TY  - JOUR
LB  - 67.
AU  - Crapo, RO
AU  - Morris, AH
AU  - Gardner, RM
TI  - Reference spirometric values using techniques and equipment that meet ATS recommendations
J2  - Am Rev Respir Dis
PY  - 1981
VL  - 123
SP  - 659
EP  - 664
UR  - https://doi.org/10.1164/arrd.1981.123.6.659
ER  - 
TY  - JOUR
LB  - 68.
AU  - Macintyre, N
AU  - Crapo, RO
AU  - Viegi, G
AU  - Johnson, DC
AU  - van der Grinten, CP
AU  - Brusasco, V
TI  - Standardisation of the single-breath determination of carbon monoxide uptake in the lung
J2  - Eur Respir J
PY  - 2005
VL  - 26
SP  - 720
EP  - 735
UR  - https://doi.org/10.1183/09031936.05.00034905
ER  - 
TY  - JOUR
LB  - 69.
AU  - Quanjer, PH
TI  - Standardized lung function testing
J2  - Bull Europ Physiopathol Respir
PY  - 1983
VL  - 19
IS  - Suppl. 5
SP  - 1
EP  - 95
ER  - 
TY  - JOUR
LB  - 70.
AU  - Ley, B
AU  - Ryerson, CJ
AU  - Vittinghoff, E
AU  - Ryu, JH
AU  - Tomassetti, S
AU  - Lee, JS
TI  - A multidimensional index and staging system for idiopathic pulmonary fibrosis
J2  - Ann Intern Med
PY  - 2012
VL  - 156
SP  - 684
EP  - 691
UR  - https://doi.org/10.7326/0003-4819-156-10-201205150-00004
ER  - 
TY  - JOUR
LB  - 71.
AU  - Lee, SH
AU  - Shim, HS
AU  - Cho, SH
AU  - Kim, SY
AU  - Lee, SK
AU  - Son, JY
TI  - Prognostic factors for idiopathic pulmonary fibrosis: clinical, physiologic, pathologic, and molecular aspects
J2  - Sarcoidosis Vasc Diffuse Lung Dis
PY  - 2011
VL  - 28
SP  - 102
EP  - 112
ER  - 
TY  - JOUR
LB  - 72.
AU  - Prasse, A
AU  - Probst, C
AU  - Bargagli, E
AU  - Zissel, G
AU  - Toews, GB
AU  - Flaherty, KR
TI  - Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis
J2  - Am J Respir Crit Care Med
PY  - 2009
VL  - 179
SP  - 717
EP  - 723
UR  - https://doi.org/10.1164/rccm.200808-1201OC
ER  - 
TY  - JOUR
LB  - 73.
AU  - Neighbors, M
AU  - Cabanski, CR
AU  - Ramalingam, TR
AU  - Sheng, XR
AU  - Tew, GW
AU  - Gu, C
TI  - Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials
J2  - Lancet Respir Med
PY  - 2018
VL  - 6
SP  - 615
EP  - 626
UR  - https://doi.org/10.1016/S2213-2600(18)30185-1
ER  - 
TY  - JOUR
LB  - 74.
AU  - King, TE
AU  - Bradford, WZ
AU  - Castro-Bernardini, S
AU  - Fagan, EA
AU  - Glaspole, I
AU  - Glassberg, MK
TI  - A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis
J2  - N Engl J Med
PY  - 2014
VL  - 370
SP  - 2083
EP  - 2092
UR  - https://doi.org/10.1056/NEJMoa1402582
ER  - 
TY  - JOUR
LB  - 75.
AU  - Xue, M
AU  - Guo, Z
AU  - Cai, C
AU  - Sun, B
AU  - Wang, H
TI  - Evaluation of the diagnostic efficacies of serological markers KL-6, SP-A, SP-D, CCL2, and CXCL13 in idiopathic interstitial pneumonia
J2  - Respiration
PY  - 2019
VL  - 98
SP  - 534
EP  - 545
UR  - https://doi.org/10.1159/000503689
ER  - 
TY  - JOUR
LB  - 76.
AU  - Raghu, G
AU  - Martinez, FJ
AU  - Brown, KK
AU  - Costabel, U
AU  - Cottin, V
AU  - Wells, AU
TI  - CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab
J2  - Eur Respir J
PY  - 2015
VL  - 46
SP  - 1740
EP  - 1750
UR  - https://doi.org/10.1183/13993003.01558-2014
ER  - 
TY  - JOUR
LB  - 77.
AU  - McGrath, EE
AU  - Lawrie, A
AU  - Marriott, HM
AU  - Mercer, P
AU  - Cross, SS
AU  - Arnold, N
TI  - Deficiency of tumour necrosis factor-related apoptosis-inducing ligand exacerbates lung injury and fibrosis
J2  - Thorax
PY  - 2012
VL  - 67
SP  - 796
EP  - 803
UR  - https://doi.org/10.1136/thoraxjnl-2011-200863
ER  - 
TY  - JOUR
LB  - 78.
AU  - Pan, T
AU  - Nielsen, LD
AU  - Allen, MJ
AU  - Shannon, KM
AU  - Shannon, JM
AU  - Selman, M
AU  - Mason, RJ
TI  - Serum SP-D is a marker of lung injury in rats
J2  - Am J Physiol Lung Cell Mol Physiol
PY  - 2002
VL  - 282
SP  - L824
EP  - L832
UR  - https://doi.org/10.1152/ajplung.00421.2000
ER  - 
TY  - JOUR
LB  - 79.
AU  - Honda, Y
AU  - Kuroki, Y
AU  - Matsuura, E
AU  - Nagae, H
AU  - Takahashi, H
AU  - Akino, T
AU  - Abe, S
TI  - Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids
J2  - Am J Respir Crit Care Med
PY  - 1995
VL  - 152
SP  - 1860
EP  - 1866
UR  - https://doi.org/10.1164/ajrccm.152.6.8520747
ER  - 
TY  - JOUR
LB  - 80.
AU  - Takahashi, H
AU  - Fujishima, T
AU  - Koba, H
AU  - Murakami, S
AU  - Kurokawa, K
AU  - Shibuya, Y
TI  - Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent
J2  - Am J Respir Crit Care Med
PY  - 2000
VL  - 162
SP  - 1109
EP  - 1114
UR  - https://doi.org/10.1164/ajrccm.162.3.9910080
ER  - 
TY  - JOUR
LB  - 81.
AU  - Dancer, RC
AU  - Wood, AM
AU  - Thickett, DR
TI  - Metalloproteinases in idiopathic pulmonary fibrosis
J2  - Eur Respir J
PY  - 2011
VL  - 38
SP  - 1461
EP  - 1467
UR  - https://doi.org/10.1183/09031936.00024711
ER  - 
TY  - JOUR
LB  - 82.
AU  - Rosas, IO
AU  - Richards, TJ
AU  - Konishi, K
AU  - Zhang, Y
AU  - Gibson, K
AU  - Lokshin, AE
TI  - MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis
J2  - PLOS Med
PY  - 2008
VL  - 5
SP  - e93
UR  - https://doi.org/10.1371/journal.pmed.0050093
ER  - 
TY  - JOUR
LB  - 83.
AU  - Fujishima, S
AU  - Shiomi, T
AU  - Yamashita, S
AU  - Yogo, Y
AU  - Nakano, Y
AU  - Inoue, T
TI  - Production and activation of matrix metalloproteinase 7 (matrilysin 1) in the lungs of patients with idiopathic pulmonary fibrosis
J2  - Arch Pathol Lab Med
PY  - 2010
VL  - 134
SP  - 1136
EP  - 1142
UR  - https://doi.org/10.1043/2009-0144-OA.1
ER  - 
TY  - JOUR
LB  - 84.
AU  - Song, JW
AU  - Do, KH
AU  - Jang, SJ
AU  - Colby, TV
AU  - Han, S
AU  - Kim, DS
TI  - Blood biomarkers MMP-7 and SP-A: predictors of outcome in idiopathic pulmonary fibrosis
J2  - Chest
PY  - 2013
VL  - 143
SP  - 1422
EP  - 1429
UR  - https://doi.org/10.1378/chest.11-2735
ER  - 
TY  - JOUR
LB  - 85.
AU  - Kakugawa, T
AU  - Yokota, S
AU  - Ishimatsu, Y
AU  - Hayashi, T
AU  - Nakashima, S
AU  - Hara, S
TI  - Serum heat shock protein 47 levels are elevated in acute interstitial pneumonia
J2  - BMC Pulm Med
PY  - 2014
VL  - 14
SP  - 48
UR  - https://doi.org/10.1186/1471-2466-14-48
ER  - 
TY  - JOUR
LB  - 86.
AU  - Amenomori, M
AU  - Mukae, H
AU  - Sakamoto, N
AU  - Kakugawa, T
AU  - Hayashi, T
AU  - Hara, A
TI  - HSP47 in lung fibroblasts is a predictor of survival in fibrotic nonspecific interstitial pneumonia
J2  - Respir Med
PY  - 2010
VL  - 104
SP  - 895
EP  - 901
UR  - https://doi.org/10.1016/j.rmed.2010.01.011
ER  - 
TY  - JOUR
LB  - 87.
AU  - Leuchte, HH
AU  - Neurohr, C
AU  - Baumgartner, R
AU  - Holzapfel, M
AU  - Giehrl, W
AU  - Vogeser, M
AU  - Behr, J
TI  - Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension
J2  - Am J Respir Crit Care Med
PY  - 2004
VL  - 170
SP  - 360
EP  - 365
UR  - https://doi.org/10.1164/rccm.200308-1142OC
ER  - 
TY  - JOUR
LB  - 88.
AU  - Song, JW
AU  - Song, JK
AU  - Kim, DS
TI  - Echocardiography and brain natriuretic peptide as prognostic indicators in idiopathic pulmonary fibrosis
J2  - Respir Med
PY  - 2009
VL  - 103
SP  - 180
EP  - 186
UR  - https://doi.org/10.1016/j.rmed.2008.11.012
ER  - 
TY  - JOUR
LB  - 89.
AU  - Maher, TM
AU  - Oballa, E
AU  - Simpson, JK
AU  - Porte, J
AU  - Habgood, A
AU  - Fahy, WA
TI  - An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study
J2  - Lancet Respir Med
PY  - 2017
VL  - 5
SP  - 946
EP  - 955
UR  - https://doi.org/10.1016/S2213-2600(17)30430-7
ER  - 
TY  - JOUR
LB  - 90.
AU  - Lode, H
AU  - Schaberg, T
AU  - Raffenberg, M
AU  - Mauch, H
TI  - Diagnostic problems in lower respiratory tract infections
J2  - J Antimicrob Chemother
PY  - 1993
VL  - 32
IS  - Suppl. A
SP  - 29
EP  - 37
UR  - https://doi.org/10.1093/jac/32.suppl_a.29
ER  - 
TY  - JOUR
LB  - 91.
AU  - Strumpf, IJ
AU  - Feld, MK
AU  - Cornelius, MJ
AU  - Keogh, BA
AU  - Crystal, RG
TI  - Safety of fiberoptic bronchoalveolar lavage in evaluation of interstitial lung disease
J2  - Chest
PY  - 1981
VL  - 80
SP  - 268
EP  - 271
UR  - https://doi.org/10.1378/chest.80.3.268
ER  - 
TY  - JOUR
LB  - 92.
AU  - Du Rand, IA
AU  - Blaikley, J
AU  - Booton, R
AU  - Chaudhuri, N
AU  - Gupta, V
AU  - Khalid, S
TI  - British Thoracic Society guidelines on diagnostic flexible bronchoscopy in adults: accredited by NICE
J2  - Thorax
PY  - 2013
VL  - 68
IS  - Suppl. 1
SP  - i1
EP  - 44
UR  - https://doi.org/10.1136/thoraxjnl-2013-203618
ER  - 
TY  - ELEC
LB  - 93.
AU  - European Medicines Agency
TI  - ICH E2A Clinical Safety Data Management: Definitions and Standards for Expedited Reporting
UR  - www.ema.europa.eu/en/ich-e2a-clinical-safety-data-management-definitions-standards-expedited-reporting
M1  - 16 April 2021
ER  - 
TY  - JOUR
LB  - 94.
AU  - Collard, HR
AU  - Calfee, CS
AU  - Wolters, PJ
AU  - Song, JW
AU  - Hong, SB
AU  - Brady, S
TI  - Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis
J2  - Am J Physiol Lung Cell Mol Physiol
PY  - 2010
VL  - 299
SP  - L3
EP  - L7
UR  - https://doi.org/10.1152/ajplung.90637.2008
ER  - 
TY  - JOUR
LB  - 95.
AU  - Wilson, AM
AU  - Clark, AB
AU  - Cahn, T
AU  - Chilvers, ER
AU  - Fraser, W
AU  - Hammond, M
TI  - Effect of co-trimoxazole (trimethoprim-sulfamethoxazole) vs. placebo on death, lung transplant, or hospital admission in patients with moderate and severe idiopathic pulmonary fibrosis: the EME-TIPAC randomized clinical trial
J2  - JAMA
PY  - 2020
VL  - 324
SP  - 2282
EP  - 2291
UR  - https://doi.org/10.1001/jama.2020.22960
ER  - 
TY  - JOUR
LB  - 96.
AU  - Yu, X
AU  - Li, X
AU  - Wang, L
AU  - Liu, R
AU  - Xie, Y
AU  - Li, S
AU  - Li, J
TI  - Pulmonary rehabilitation for exercise tolerance and quality of life in IPF patients: a systematic review and meta-analysis
J2  - Biomed Res Int
PY  - 2019
VL  - 2019
SP  - 8498603
UR  - https://doi.org/10.1155/2019/8498603
ER  - 
TY  - JOUR
LB  - 97.
AU  - Schünemann, HJ
AU  - Griffith, L
AU  - Jaeschke, R
AU  - Goldstein, R
AU  - Stubbing, D
AU  - Guyatt, GH
TI  - Evaluation of the minimal important difference for the feeling thermometer and the St. George’s Respiratory Questionnaire in patients with chronic airflow obstruction
J2  - J Clin Epidemiol
PY  - 2003
VL  - 56
SP  - 1170
EP  - 1176
UR  - https://doi.org/10.1016/S0895-4356(03)00115-X
ER  - 
TY  - JOUR
LB  - 98.
AU  - Jones, PW
AU  - Quirk, FH
AU  - Baveystock, CM
AU  - Littlejohns, P
TI  - A self-complete measure of health status for chronic airflow limitation. The St. George’s Respiratory Questionnaire
J2  - Am Rev Respir Dis
PY  - 1992
VL  - 145
SP  - 1321
EP  - 1327
UR  - https://doi.org/10.1164/ajrccm/145.6.1321
ER  - 
TY  - JOUR
LB  - 99.
AU  - Ryerson, CJ
AU  - Abbritti, M
AU  - Ley, B
AU  - Elicker, BM
AU  - Jones, KD
AU  - Collard, HR
TI  - Cough predicts prognosis in idiopathic pulmonary fibrosis
J2  - Respirology
PY  - 2011
VL  - 16
SP  - 969
EP  - 975
UR  - https://doi.org/10.1111/j.1440-1843.2011.01996.x
ER  - 
TY  - JOUR
LB  - 100.
AU  - van Manen, MJ
AU  - Birring, SS
AU  - Vancheri, C
AU  - Cottin, V
AU  - Renzoni, EA
AU  - Russell, AM
AU  - Wijsenbeek, MS
TI  - Cough in idiopathic pulmonary fibrosis
J2  - Eur Respir Rev
PY  - 2016
VL  - 25
SP  - 278
EP  - 286
UR  - https://doi.org/10.1183/16000617.0090-2015
ER  - 
TY  - JOUR
LB  - 101.
AU  - Hewson, T
AU  - McKeever, TM
AU  - Gibson, JE
AU  - Navaratnam, V
AU  - Hubbard, RB
AU  - Hutchinson, JP
TI  - Timing of onset of symptoms in people with idiopathic pulmonary fibrosis
J2  - Thorax
PY  - 2018
VL  - 73
SP  - 683
EP  - 685
UR  - https://doi.org/10.1136/thoraxjnl-2017-210177
ER  - 
TY  - ELEC
LB  - 102.
AU  - National Institute for Health and Care Excellence
TI  - Pirfenidone for Treating Idiopathic Pulmonary Fibrosis: Technology Appraisal Guidance 282
PY  - 2013
UR  - www.nice.org.uk/guidance/ta282
M1  - 19 January 2021
ER  - 
TY  - JOUR
LB  - 103.
AU  - Richeldi, L
AU  - du Bois, RM
AU  - Raghu, G
AU  - Azuma, A
AU  - Brown, KK
AU  - Costabel, U
TI  - Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis
J2  - N Engl J Med
PY  - 2014
VL  - 370
SP  - 2071
EP  - 2082
UR  - https://doi.org/10.1056/NEJMoa1402584
ER  - 
TY  - ELEC
LB  - 104.
AU  - National Institute for Health and Care Excellence
TI  - Nintedanib for Treating Idiopathic Pulmonary Fibrosis: Technology Appraisal Guidance 379
PY  - 2016
UR  - www.nice.org.uk/guidance/ta379
M1  - 19 January 2021
ER  - 
TY  - JOUR
LB  - 105.
AU  - Costabel, U
AU  - Albera, C
AU  - Lancaster, LH
AU  - Lin, CY
AU  - Hormel, P
AU  - Hulter, HN
AU  - Noble, PW
TI  - An open-label study of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (RECAP)
J2  - Respiration
PY  - 2017
VL  - 94
SP  - 408
EP  - 415
UR  - https://doi.org/10.1159/000479976
ER  - 
TY  - JOUR
LB  - 106.
AU  - Fisher, M
AU  - Nathan, SD
AU  - Hill, C
AU  - Marshall, J
AU  - Dejonckheere, F
AU  - Thuresson, PO
AU  - Maher, TM
TI  - Predicting life expectancy for pirfenidone in idiopathic pulmonary fibrosis
J2  - J Manag Care Spec Pharm
PY  - 2017
VL  - 23
IS  - Suppl. 3-b
SP  - 17
EP  - 24
UR  - https://doi.org/10.18553/jmcp.2017.23.3-b.s17
ER  - 
TY  - JOUR
LB  - 107.
AU  - Lancaster, L
AU  - Crestani, B
AU  - Hernandez, P
AU  - Inoue, Y
AU  - Wachtlin, D
AU  - Loaiza, L
TI  - Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials
J2  - BMJ Open Respir Res
PY  - 2019
VL  - 6
SP  - e000397
UR  - https://doi.org/10.1136/bmjresp-2018-000397
ER  - 
TY  - JOUR
LB  - 108.
AU  - Nathan, SD
AU  - Costabel, U
AU  - Albera, C
AU  - Behr, J
AU  - Wuyts, WA
AU  - Kirchgaessler, KU
TI  - Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment
J2  - Respir Med
PY  - 2019
VL  - 153
SP  - 44
EP  - 51
UR  - https://doi.org/10.1016/j.rmed.2019.04.016
ER  - 
TY  - JOUR
LB  - 109.
AU  - du Bois, RM
AU  - Weycker, D
AU  - Albera, C
AU  - Bradford, WZ
AU  - Costabel, U
AU  - Kartashov, A
TI  - Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference
J2  - Am J Respir Crit Care Med
PY  - 2011
VL  - 184
SP  - 1382
EP  - 1389
UR  - https://doi.org/10.1164/rccm.201105-0840OC
ER  - 
TY  - JOUR
LB  - 110.
AU  - Fujita, H
AU  - Sakamoto, N
AU  - Ishimatsu, Y
AU  - Kakugawa, T
AU  - Hara, S
AU  - Hara, A
TI  - Effects of doxycycline on production of growth factors and matrix metalloproteinases in pulmonary fibrosis
J2  - Respiration
PY  - 2011
VL  - 81
SP  - 420
EP  - 430
UR  - https://doi.org/10.1159/000324080
ER  - 
TY  - JOUR
LB  - 111.
AU  - Bhattacharyya, P
AU  - Nag, S
AU  - Bardhan, S
AU  - Acharya, D
AU  - Paul, R
AU  - Dey, R
TI  - The role of long-term doxycycline in patients of idiopathic pulmonary fibrosis: the results of an open prospective trial
J2  - Lung India
PY  - 2009
VL  - 26
SP  - 81
EP  - 85
UR  - https://doi.org/10.4103/0970-2113.53231
ER  - 
TY  - JOUR
LB  - 112.
AU  - Tsubouchi, K
AU  - Araya, J
AU  - Minagawa, S
AU  - Hara, H
AU  - Ichikawa, A
AU  - Saito, N
TI  - Azithromycin attenuates myofibroblast differentiation and lung fibrosis development through proteasomal degradation of NOX4
J2  - Autophagy
PY  - 2017
VL  - 13
SP  - 1420
EP  - 1434
UR  - https://doi.org/10.1080/15548627.2017.1328348
ER  - 
TY  - JOUR
LB  - 113.
AU  - Wuyts, WA
AU  - Willems, S
AU  - Vos, R
AU  - Vanaudenaerde, BM
AU  - De Vleeschauwer, SI
AU  - Rinaldi, M
TI  - Azithromycin reduces pulmonary fibrosis in a bleomycin mouse model
J2  - Exp Lung Res
PY  - 2010
VL  - 36
SP  - 602
EP  - 614
UR  - https://doi.org/10.3109/01902148.2010.492895
ER  - 
TY  - JOUR
LB  - 114.
AU  - Macaluso, C
AU  - Maritano Furcada, J
AU  - Alzaher, O
AU  - Chaube, R
AU  - Chua, F
AU  - Wells, AU
TI  - The potential impact of azithromycin in idiopathic pulmonary fibrosis
J2  - Eur Respir J
PY  - 2019
VL  - 53
SP  - 1800628
UR  - https://doi.org/10.1183/13993003.00628-2018
ER  - 
TY  - JOUR
LB  - 115.
AU  - Kawamura, K
AU  - Ichikado, K
AU  - Yasuda, Y
AU  - Anan, K
AU  - Suga, M
TI  - Azithromycin for idiopathic acute exacerbation of idiopathic pulmonary fibrosis: a retrospective single-center study
J2  - BMC Pulm Med
PY  - 2017
VL  - 17
SP  - 94
UR  - https://doi.org/10.1186/s12890-017-0437-z
ER  - 
TY  - JOUR
LB  - 116.
AU  - Naik, PK
AU  - Bozyk, PD
AU  - Bentley, JK
AU  - Popova, AP
AU  - Birch, CM
AU  - Wilke, CA
TI  - Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis
J2  - Am J Physiol Lung Cell Mol Physiol
PY  - 2012
VL  - 303
SP  - L1046
EP  - L1056
UR  - https://doi.org/10.1152/ajplung.00139.2012
ER  - 
TY  - JOUR
LB  - 117.
AU  - Parker, D
AU  - Prince, A
TI  - Staphylococcus aureusinduces type I IFN signaling in dendritic cells via TLR9
J2  - J Immunol
PY  - 2012
VL  - 189
SP  - 4040
EP  - 4046
UR  - https://doi.org/10.4049/jimmunol.1201055
ER  - 
TY  - JOUR
LB  - 118.
AU  - Raghu, G
AU  - Freudenberger, TD
AU  - Yang, S
AU  - Curtis, JR
AU  - Spada, C
AU  - Hayes, J
TI  - High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis
J2  - Eur Respir J
PY  - 2006
VL  - 27
SP  - 136
EP  - 142
UR  - https://doi.org/10.1183/09031936.06.00037005
ER  - 
TY  - JOUR
LB  - 119.
AU  - Savarino, E
AU  - Carbone, R
AU  - Marabotto, E
AU  - Furnari, M
AU  - Sconfienza, L
AU  - Ghio, M
TI  - Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients
J2  - Eur Respir J
PY  - 2013
VL  - 42
SP  - 1322
EP  - 1331
UR  - https://doi.org/10.1183/09031936.00101212
ER  - 
TY  - JOUR
LB  - 120.
AU  - Kitsios, GD
AU  - Rojas, M
AU  - Kass, DJ
AU  - Fitch, A
AU  - Sembrat, JC
AU  - Qin, S
TI  - Microbiome in lung explants of idiopathic pulmonary fibrosis: a case–control study in patients with end-stage fibrosis
J2  - Thorax
PY  - 2018
VL  - 73
SP  - 481
EP  - 484
UR  - https://doi.org/10.1136/thoraxjnl-2017-210537
ER  - 
TY  - JOUR
LB  - 121.
AU  - Jenkins, G
TI  - A big beautiful wall against infection
J2  - Thorax
PY  - 2018
VL  - 73
SP  - 485
UR  - https://doi.org/10.1136/thoraxjnl-2017-211220
ER  - 
TY  - JOUR
LB  - 122.
AU  - Wüst, J
AU  - Wilkins, TD
TI  - Susceptibility of anaerobic bacteria to sulfamethoxazole/trimethoprim and routine susceptibility testing
J2  - Antimicrob Agents Chemother
PY  - 1978
VL  - 14
SP  - 384
EP  - 390
UR  - https://doi.org/10.1128/AAC.14.3.384
ER  - 
TY  - JOUR
LB  - 123.
AU  - Wolter, J
AU  - Seeney, S
AU  - Bell, S
AU  - Bowler, S
AU  - Masel, P
AU  - McCormack, J
TI  - Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial
J2  - Thorax
PY  - 2002
VL  - 57
SP  - 212
EP  - 216
UR  - https://doi.org/10.1136/thorax.57.3.212
ER  - 
TY  - JOUR
LB  - 124.
AU  - Prins, HJ
AU  - Daniels, JM
AU  - Lindeman, JH
AU  - Lutter, R
AU  - Boersma, WG
TI  - Effects of doxycycline on local and systemic inflammation in stable COPD patients, a randomized clinical trial
J2  - Respir Med
PY  - 2016
VL  - 110
SP  - 46
EP  - 52
UR  - https://doi.org/10.1016/j.rmed.2015.10.009
ER  - 
TY  - JOUR
LB  - 125.
AU  - Wolters, PJ
AU  - Collard, HR
AU  - Jones, KD
TI  - Pathogenesis of idiopathic pulmonary fibrosis
J2  - Annu Rev Pathol
PY  - 2014
VL  - 9
SP  - 157
EP  - 179
UR  - https://doi.org/10.1146/annurev-pathol-012513-104706
ER  - 
TY  - JOUR
LB  - 126.
AU  - Ruskin, J
AU  - LaRiviere, M
TI  - Low-dose co-trimoxazole for prevention ofPneumocystis cariniipneumonia in human immunodeficiency virus disease
J2  - Lancet
PY  - 1991
VL  - 337
SP  - 468
EP  - 471
UR  - https://doi.org/10.1016/0140-6736(91)93402-U
ER  - 
TY  - JOUR
LB  - 127.
AU  - Chintu, C
AU  - Bhat, GJ
AU  - Walker, AS
AU  - Mulenga, V
AU  - Sinyinza, F
AU  - Lishimpi, K
TI  - Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial
J2  - Lancet
PY  - 2004
VL  - 364
SP  - 1865
EP  - 1871
UR  - https://doi.org/10.1016/S0140-6736(04)17442-4
ER  - 
TY  - JOUR
LB  - 128.
AU  - Collard, HR
AU  - Ryerson, CJ
AU  - Corte, TJ
AU  - Jenkins, G
AU  - Kondoh, Y
AU  - Lederer, DJ
TI  - Acute exacerbation of idiopathic pulmonary fibrosis. An International Working Group Report
J2  - Am J Respir Crit Care Med
PY  - 2016
VL  - 194
SP  - 265
EP  - 275
UR  - https://doi.org/10.1164/rccm.201604-0801CI
ER  -